Several real-world studies have also shown that first- or second-generation EGFR-TKIs combined with AATs yield better PFS outcomes in treatment-naïve EGFR-mutant NSCLC [18,19,20]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.